Evidence map›Paper›PMID 41100408›Full record

ArticleThe Journal of dermatology2025

Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis.

Yuki Kuma, Makiko Kido-Nakahara, Yoko Kuba-Fuyuno, Takashi Matsumoto, Yoshinao Oda, Masatoshi Eto, Takeshi Nakahara

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuki KumaDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-5131-5585
Makiko Kido-NakaharaDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-4169-1309
Yoko Kuba-FuyunoDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-6209-7923
Takashi MatsumotoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Yoshinao OdaDepartment of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-9636-1182
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-3312-9930
Takeshi NakaharaDepartment of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0003-2811-8273

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.

Indexed as

Antibodies, MonoclonalDrug EruptionsImmune Checkpoint InhibitorsUrinary Bladder NeoplasmsAgedCell Adhesion MoleculesFemaleHumansKeratinocytesMaleMiddle AgedSkinAntibodies, MonoclonalCell Adhesion Moleculesenfortumab vedotinImmune Checkpoint InhibitorsEnfortumab vedotinimmune checkpoint inhibitorsskin toxicityurothelial carcinomaantibody‐drug conjugate

Identifiers

PMID41100408
PMCPMC12530469

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.